Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 20, 2015 | VP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 1,896 | -- | 33,104 | |
| Mar 20, 2015 | VP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,624 | -- | 25,376 | |
| Mar 20, 2015 | VP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,463 | -- | 31,537 | |
| Mar 20, 2015 | VP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,812 | -- | 42,188 | |
| Mar 20, 2015 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,648 | $11.51 | 60,648 | |
| Mar 20, 2015 | VP, Patient Advocacy | Open market or private sale of non-derivative or derivative security | Form 4 | 10,648 | $11.51 | 50,000 | |
| Mar 20, 2015 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,374 | -- | 30,626 | |
| Mar 20, 2015 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,462 | -- | 31,538 | |
| Mar 20, 2015 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,812 | -- | 42,188 | |
| Mar 20, 2015 | VP, Regulatory Affairs | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,110 | $11.51 | 60,110 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.